Rocket Pharma swings to Q2 FY26 net income of $123.2 million; R&D expenses fall 30.92% to $29.5 million
RCKT•Q2 FY26 results
Rocket Pharmaceuticals turned profitable in Q2 2026, posting net income of $123.2 million, versus a net loss of $68.9 million a year earlier.
Expenses declined
R&D expense fell 30.92% to $29.5 million, driven by lower manufacturing and development costs plus reduced stock-based compensation and headcount.
G&A expense dropped 30.4% to $17.4 million, on lower commercial preparation spending, stock-based compensation, and legal costs.
Program update and runway
All three initial RP-A501 Danon patients cleared the safety observation period with no TMA or capillary leak; cash runway forecast into Q2 2028.
Other income and cash position
Other income climbed to $178.8 million on a net $178.2 million gain from selling a Priority Review Voucher, lifting cash to $283.7 million.
